🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Scienture Holdings, Inc. SCNX PHARMA

Healthcare · Pharmaceutical Retailers · United States
https://scienture.com
Company Profile ↓
$0.36
-83.62% 1Y
Mkt Cap$14.78M
P/E-0.18
P/B0.20
52W High$2.60
52W Low$0.24
Book Value$1.56
EPS (TTM)$-2.03

Company Overview

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.17.

Recent Developments

  • Dec 2025 Revenue of $431.61K (+215.9% YoY); net profit $-41.51M.
  • Trailing 12 Months Year-on-year growth — revenue +449.1%, earnings -557.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR -6.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-6.41%
1 Year:449.10%

Compounded Profit Growth

5 Years:-
1 Year:-557.90%

Stock Price Performance

1 Year:-83.62%
6 Months:-6.50%
3 Months:+3.32%
1 Month:-4.29%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 5% of range
$0.24 $2.60
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)38.66 · Neutral
Price Performance
1M-4.29%
3M+3.32%
6M-6.50%
1Y-83.62%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -6.4% CAGR over 5 years.
  • Trading 86.0% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.18
Industry PE
24.83
Forward P/E
-
PEG Ratio
-
Book Value
$1.56
Price to Book
0.20
P/S
15.67
EV/EBITDA
-1.24
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-6.41%
Profit 5Y
-
Revenue (YoY)
449.10%
Earnings (YoY)
-557.90%

Profitability & Returns

ROCE
-52.30%
ROE
-53.47%
ROA
-8.93%
Profit Margin
0.00%
Op Margin
-
Gross Margin
87.72%
EPS (Latest Qtr)
$-0.08
EPS (TTM)
$-2.03

Balance Sheet & Liquidity

Debt/Equity
0.17
Quick Ratio
2.83
Current Ratio
3.04
Debt
$10.69M
Total Assets
$80.66M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
13.17%
Chg in Prom Hold
-0.14%
FII / Inst Holding
5.30%
Chg in FII Hold
1.55%

Financial Snapshot

Enterprise Value
$14.78M
Total Revenue (TTM)
$821.32K
EBITDA
$-12.36M
Free Cash Flow
$-7.61M
Operating Cash Flow
$-14.44M
Shares Outstanding
41.06M
Gross Margin
87.72%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SCNX Scienture Holdings, Inc. PHARMA 0.36 -0.18 $14.78M 0.00% -52.30% -53.47% -6.41% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue ---------------837.69K847.47K1.51M1.92M2.31M2.20M6.59M6.33M3.05M1.90M2.55M3.24M3.28M2.06M493.32K366.53K392.29K-18.70K64.86K10.26K-590.05K56.33K
Gross Profit 132.34K-45.27K97.41K236.53K295.54K465.67K785.19K937.24K628.92K587.73K610.83K745.94K704.73K735.87K852.92K837.69K845.13K1.15M1.16M1.31M1.64M2.00M1.93M1.38M841.39K1.28M1.34M1.17M1.37M73.22K67.14K39.59K--7033.88K673-574.62K53.85K
Operating Income -183.93K-282.83K-344.52K-300.03K-349.83K-442.65K-26.45K-76.56K-130.28K-577.58K-245.22K141.45K48.78K89.61K98.73K31.45K91.83K171.76K132.71K177.85K188.23K-535.28K145.82K-644.25K-2.57M-1.30M-968.57K-1.10M-218.76K-806.09K-599.78K-761.68K-5.49M-1.50M-3.50M-3.57M-5.16M-4.36M-3.51M
Net Income -184.50K-283.68K-922.00K-301.02K-351.88K-443.62K-54.36K-123.76K-372.38K-1.10M-842.88K79.73K-6.84K76.19K82.27K20.51K94.25K125.23K57.98K27.57K180.30K-542.59K138.39K-651.52K-2.58M-1.30M-965.84K-1.11M-503.00K-677.95K-1.97M-3.53M21.25M-1.83M-3.18M-3.06M-6.72M-3.61M-3.40M
Diluted EPS 0.00-0.01-0.03-0.01-0.01-0.010.000.00-0.01-0.04-0.030.000.000.000.000.000.000.020.010.000.02-0.070.02-0.08-0.32-0.16-0.12-1.99-0.91-1.01-2.90-4.5716.77-1.30-1.34-0.33-0.48-0.19-0.08
R&D Expense ----------------------------------1.25M574.68K843.55K169.34K793.98K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 955.88K1.50M2.91M2.48M2.93M3.83M7.44M17.12M9.89M10.25M1.36M136.64K431.61K
Gross Profit 11.81K1.06M2.72M2.48M2.93M3.38M4.87M5.71M4.75M5.52M49.03K6.00K331.48K
Operating Income -2.08M-1.43M-137.07K-1.01M395.10K-87.62K125.22K-2.51M-5.29M-2.92M-4.40M-14.70M-42.59M
Net Income -2.09M-2.01M-1.12M-2.76M288.98K9.04K-284.43K-2.54M-5.32M-3.47M-17.84M9.07M-41.51M
Diluted EPS -0.15-0.07-0.04-0.090.010.00-0.05--0.65-6.13-23.352.48-2.70
R&D Expense -----------2.24M1.96M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -403.87K1.22M2.03M337.12K617.48K2.23M5.57M9.79M5.77M3.71M12.53M104.85M84.18M
Total Equity -130.87K668.44K267.02K-1.15M-311.93K844.67K4.14M8.68M3.77M763.14K542.35K79.07M70.12M
Cash & Equivalents 3.38K84.32K695.82K78.71K14.68K183.91K869.56K2.87M5.92M3.12M1.09M151.91K-6.66M
Long Term Debt -----666.52K522.05K225.00K----2.90M-
Total Liabilities --553.68K1.76M1.49M929.41K1.38M1.43M1.11M2.00M3.37M11.99M25.78M14.06M
Current Liabilities -273.00K553.68K1.76M1.47M525.36K860.37K520.82K842.24K926.03K2.15M11.56M7.91M2.74M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -844.58K-1.06M90.39K-503.53K171.67K273.39K141.78K-2.21M-2.57M-1.53M-2.23M-14.27M-13.38M
Investing Cash Flow 10.99K---78.00K0-265.28K-332.25K-37.51K-22.60K-427.85K-275.72K27.55M-
Financing Cash Flow 936.51K1.69M1.36M--2.44K677.54K2.19M5.30M-208.18K-35.17K1.41M-12.98M19.73M
Capital Expenditure -10.99K-------37.51K-22.60K---12.00K-
Free Cash Flow -855.57K-------2.25M-2.59M---14.28M-
Dividends Paid -----------14.86M-

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 1.2%70.6%93.5%100.0%100.0%88.3%65.5%33.3%48.0%53.8%3.6%4.4%76.8%
Operating Margin % -218.0%-95.7%-4.7%-40.6%13.5%-2.3%1.7%-14.6%-53.5%-28.4%-322.4%-10,758.7%-9,867.9%
Net Margin % -218.8%-134.5%-38.4%-111.2%9.9%0.2%-3.8%-14.8%-53.8%-33.9%-1,308.3%6,634.7%-9,618.0%
ROE % -1,598.0%-301.0%-418.4%240.4%-92.6%1.1%-6.9%-29.2%-141.0%-455.0%-3,290.0%11.5%-59.2%
ROCE % -1,592.5%-214.2%-51.3%88.6%428.9%-6.4%2.5%-28.0%-109.3%-186.5%-450.2%-15.2%-52.3%

Shareholding Pattern

Insiders
13.17%
Institutions
5.30%
Public Float
6.10%

Top Institutional Holders

#Holder% HeldSharesValue
1 Vanguard Capital Management LLC 1.24% 510.39K $160.01K
2 Geode Capital Management, LLC 0.82% 334.97K $105.01K
3 Susquehanna International Group, LLP 0.57% 235.12K $73.71K
4 Vanguard Fiduciary Trust Co 0.48% 198.06K $62.09K
5 Citadel Advisors Llc 0.40% 164.85K $51.68K
6 HRT Financial LP 0.32% 132.67K $41.59K
7 Xtx Topco Ltd 0.26% 104.80K $32.85K
8 Northern Trust Corporation 0.21% 87.61K $27.46K
9 UBS Group AG 0.21% 85.92K $26.93K
10 Jane Street Group, LLC 0.18% 75.73K $23.74K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SCNX

Google News Sun, 23 Aug 2026

SCNX | Scienture Holdings, Inc. Common Financials - Revenue Breakdown - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5LVVloLXVocG9lNU1IZlVibWQwX2NnMWtLcExPNkxuVlhfY1cxMzlCUm1zdXRXUWljQUlZcmkxSHZsSWJVS2xLV25lSW1qemQzdXJOa3dMSEptY2Z5SDlFNHpOVVpoWmJBcllwRFF2VzdHTVA5OEpj?oc=5" target="_blank">SCNX | …

Google News hu, 03 Sep 2026

Enterprise value to revenue forward of Scienture Holdings, Inc. – NASDAQ:SCNX - tradingview.com

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNUDdQZTVJQWN0N3ZyR2cycHZiZWk4eHk2aElBTUpJdXA3cDlwdlN0eW8xN3B2c21hTTl6ZlF2UUc3S3psSFI1ZEF0RU9ISC1EaTV3LTFkT28zWFRGZTVPeEJsVXJaN2d5UDB3UXh1eEg0WFA0LXJPbHk5b1JHWnJ3bGd1T3RBeDcwVWNUMT…

Google News Wed, 12 Aug 2026

Scienture Begins Nationwide Distribution of 10 mg Opioid-Overdose Spray - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPazBrOURZMHZ3Ymw3RlZzM25xTjZ6N2NmQjJ3TDZMblFPaVZ1a3ZZelNfOHFyVWFpTEwweW5PNGFGWXJ5elpMSmJ1ZEhNdlduZkZ1VmFzT0JLZmtKTTBhTjFNdU03aF9oMWVLU1J0bUlhS1FoaVl3eE9HTWhMVm1kWnBJZmRGTHZnN3RMSn…

Google News Wed, 27 May 2026

SCNX - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE0wUURRcVF5NDlVdXNzV0VYOEo2STdsTnI1WGJQalVHVkcxZWlHZE9yZUlnVnlYdFZtczBUOC0yVThpRkMtcHc?oc=5" target="_blank">SCNX</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

Google News ue, 16 Jun 2026

Maxim Group Maintains Scienture Holdings(SCNX.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNTGgwYUJianFMOTlsd0VBOWdrWTUxd3FBMHlGaGUxTnNyMGtpdm0tRXk3ZGhXVEpySjFRT3VoWEVLTnkxVVZnRUJHbGU0WFg0T3RPbWZhTFJUSlJSX1lfbEZkakdTZjNfLU55ZEdWWF9CcWpsNDRnRzRyQy1zRTNvTS1kc3dYN1ptblZ6R1…

Google News Mon, 27 Jul 2026

When Will Scienture Holdings, Inc. (NASDAQ:SCNX) Become Profitable? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxOcld5aXg4U09LYUhPcnFkZzNEYUZVUXROWXl2ejlscC1qLWZiamduek5fMmhVOGYxQmd6V0NrM1FBYWhDUUJNOEZsZXc5UVNwMENkaEUteEt4Q09RVmlGcThCdHd3RHBwMEJKVEVxTTZPbE14VWdPQ3NBRWc3VVJmRklVUFBNSFN0MG4ybW…

SCNX — Frequently Asked Questions

What is the current share price of Scienture Holdings, Inc. (SCNX)?

As of 2026-09-19 21:16 PDT, Scienture Holdings, Inc. (SCNX) trades at $0.36 on NasdaqCM. Its 52-week range is $0.24 to $2.60.

What is the market capitalisation of SCNX?

Scienture Holdings, Inc. (SCNX) has a market capitalisation of $14.78M on NasdaqCM.

What is the P/E ratio of SCNX?

SCNX trades at a trailing price-to-earnings (P/E) ratio of -0.18. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.20.

What is the return on equity (ROE) of SCNX?

SCNX has a return on equity (ROE) of -53.47%. Its return on capital employed (ROCE) is -52.30%.

Is SCNX a good stock to buy?

This page provides a data-driven analysis of Scienture Holdings, Inc. (SCNX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space